To assess if endogenous KMT2D regulates the expression of endogenous GR in these cells, we used CRISPR/Cas9 to target KMT2D in L363 cells, a GC-sensitive multiple myeloma cell line (26). This evidence concerns the gene KMT2D and AL amyloidosis.